Jefferies Raises Price Target on China Biologic Products (CBPO) to $155; Reiterates Buy
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Jefferies reiterated a Buy rating on China Biologic Products (NASDAQ: CBPO), and raised the price target to $155.00 (from $136.00), following the company's 2Q earnings report. Total sales revenue was up 15.6% yoy and Non-GAAP net income was up 23.0% yoy despite fx drag.
Analyst Kevin Zhao commented, "CBPO posted strong 2Q16 results and encouraging updates. Key highlights include: No. 1 market shares in albumin, IVIG and PP in 1H16; approved plan to increase stake in Guizhou subsidiary; ASP uptrend; smooth ramp-up of Hebei centre. In the coming months, a few big provinces are publishing tendering results, which we believe will further consolidate ASP uptrend and boost market sentiment on the sector. Maintain Buy and raise PT to US$155."
Shares of China Biologic Products closed at $134.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Raises Price Target on VMware (VMW) to $91 Following Better Than Expected 3Q
- Wedbush Raises price Target on NCR Corp. (NCR) Following 3Q; Reiterates Neutral
- Jefferies Reiterates Buy on NuVasive (NUVA) Following 3Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesJefferies & Co, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!